• Thiothixene: Rethinking Antipsychotic Research for Translati

  2026-06-25

  Explore how Thiothixene, a classic antipsychotic agent, is reshaping translational research by bridging dopamine signaling antagonism with innovative immune modulation. This article delivers mechanistic insights, protocol guidance, and strategic context for advancing both neuropsychiatric and immunological discovery—moving far beyond standard product summaries.

• Mitoxantrone: Beyond Resistance—Advanced Insights for Transl

  2026-06-24

  Explore Mitoxantrone as a topoisomerase II inhibitor and apoptosis inducer in B-CLL cells, with a deep dive into resistance mechanisms and practical assay optimization. This article offers new scientific perspectives and actionable guidance for translational oncology researchers.

• BCL-XL Inhibitor A-1155463: Selectivity and Evidence in Canc

  2026-06-23

  BCL-XL inhibitor A-1155463 is a potent, selective compound for targeting BCL-XL in cancer research. Its nanomolar affinity and superior selectivity over earlier inhibitors enable precise apoptosis induction in BCL-XL-dependent cells. Supported by robust preclinical evidence, A-1155463 is a critical tool in dissecting drug resistance mechanisms in solid tumors and hematological malignancies.

• Elobixibat Hydrate in Chronic Idiopathic Constipation: Mecha

  2026-06-23

  This article reviews how elobixibat hydrate, as detailed by Acosta and Camilleri, functions as a selective ileal bile acid transporter inhibitor to improve chronic idiopathic constipation (CIC). By elucidating its mechanism, clinical impact, and comparison with standard therapies, the article informs research design and translational strategies in gastrointestinal pharmacology.

• Dabigatran Etexilate: Direct Thrombin Inhibitor in Coagulati

  2026-06-22

  Dabigatran etexilate delivers precise, rapid, and predictable inhibition of thrombin for advanced anticoagulant research, especially in atrial fibrillation and stroke prevention models. Distinct from traditional agents, it streamlines workflows, reduces monitoring burdens, and offers unique troubleshooting flexibility for both in vitro and in vivo studies.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine:

  2026-06-22

  5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine from APExBIO enables robust, reproducible α2-adrenergic receptor agonist studies, especially in immune modulation and osteosarcoma recurrence models. This article details applied workflows, critical protocol parameters, and practical troubleshooting for maximizing translational insights.

• Practical Use of Annexin V-FITC/7-AAD Apoptosis Kit (K1139)

  2026-06-21

  The Annexin V-FITC/7-AAD Apoptosis Kit is designed for rapid, reliable detection of apoptotic and necrotic cells, streamlining cell viability and cytotoxicity assays via flow cytometry or fluorescence microscopy. This product is best suited for workflows focused on phosphatidylserine exposure and membrane integrity—not for deep mechanistic or pathway analyses.

• Acifran and the Next Frontier in Lipid Metabolism Research

  2026-06-20

  This article unpacks the mechanistic and translational impact of Acifran, a selective HM74A/GPR109A and GPR109B agonist, in lipid metabolism research. Integrating structural biology breakthroughs and practical workflow strategies, we chart how Acifran is empowering a new era of precision metabolic disorder research and outline recommendations for translational scientists seeking to advance the field.

• DAPT (GSI-IX): Precision Tools for Notch Pathway Modulation

  2026-06-19

  DAPT (GSI-IX) empowers researchers with selective, reproducible γ-secretase inhibition, streamlining Notch pathway studies in disease modeling and organoid systems. With data-backed workflows and troubleshooting, this guide clarifies how to harness DAPT’s full potential across neurodegeneration, cancer, and regenerative medicine.

• Neurotensin: Precision Neurotensin Receptor 1 Activator for

  2026-06-19

  APExBIO’s Neurotensin (CAS 39379-15-2) sets the standard for dissecting GPCR trafficking and miRNA regulation in gastrointestinal and neural systems. This guide details practical workflows, addresses spectral interference, and provides actionable troubleshooting tips for robust, reproducible research.

• Targeted CRISPRi Delivery to Adipocytes Ameliorates Obesity

  2026-06-18

  This study demonstrates a targeted, nonviral CRISPR interference approach to selectively silence Fabp4 in white adipocytes, resulting in reduced obesity, inflammation, hepatic steatosis, and improved insulin sensitivity in obese mice. The findings offer a promising advance in metabolic disorder research by overcoming delivery and specificity limitations of earlier gene therapies.

• Alda 1 as a Precision ALDH2 Activator: Redefining Cardiac Re

  2026-06-18

  Explore how Alda 1, a potent ALDH2 activator, uniquely advances cardiac regeneration and aldehyde detoxification research. This article delivers an in-depth analysis of Alda 1’s mechanism, assay design, and translational implications, offering perspectives not found in existing resources.

• GPR107 Deficiency Exacerbates Diabetic Nephropathy via Calci

  2026-06-17

  Xu et al. reveal that loss of G protein-coupled receptor 107 (GPR107) aggravates diabetic nephropathy by disrupting podocyte-mediated collagen IV homeostasis. Their mechanistic study links impaired endocytosis and AT1R/Ca2+ signaling to glomerular basement membrane thickening, providing new insights and potential therapeutic avenues.

• PR-619: Practical Guide for Deubiquitylating Enzyme Inhibiti

  2026-06-17

  PR-619 enables broad, reversible inhibition of cysteine-dependent deubiquitylating enzymes (DUBs) in cell-based studies, supporting research into ubiquitination pathways, autophagy, and disease models. It is not suitable where aqueous solubility or strict DUB selectivity is required, and care must be taken with cytotoxicity at low micromolar concentrations.

• Homoharringtonine: Bridging Cancer Biology and Antiviral Fro

  2026-06-16

  This thought-leadership article presents translational researchers with a mechanistic deep dive into Homoharringtonine, a cytotoxic alkaloid uniquely positioned at the convergence of leukemia research and SARS-CoV-2 antiviral discovery. We dissect its ribosomal mechanism, summarize pivotal evidence for rapid viral clearance, map out competitive and workflow considerations, and offer strategic guidance for leveraging Homoharringtonine in next-gen translational pipelines. Anchored by recent peer-reviewed findings, this piece reframes Homoharringtonine not as a single-purpose cytotoxic agent, but as a molecular bridge for new experimental paradigms.

444 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page